TMCI Stock Overview
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States.
Treace Medical Concepts Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$22.66|
|52 Week High||US$29.61|
|52 Week Low||US$12.48|
|1 Month Change||13.81%|
|3 Month Change||48.49%|
|1 Year Change||-22.79%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-11.24%|
Recent News & Updates
|TMCI||US Medical Equipment||US Market|
Return vs Industry: TMCI exceeded the US Medical Equipment industry which returned -32.6% over the past year.
Return vs Market: TMCI underperformed the US Market which returned -21.6% over the past year.
|TMCI Average Weekly Movement||7.6%|
|Medical Equipment Industry Average Movement||8.4%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.9%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: TMCI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: TMCI's weekly volatility (8%) has been stable over the past year.
About the Company
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system.
Treace Medical Concepts Fundamentals Summary
|TMCI fundamental statistics|
Is TMCI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TMCI income statement (TTM)|
|Cost of Revenue||US$21.71m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.71|
|Net Profit Margin||-34.46%|
How did TMCI perform over the long term?See historical performance and comparison
Is TMCI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for TMCI?
Other financial metrics that can be useful for relative valuation.
|What is TMCI's n/a Ratio?|
Price to Sales Ratio vs Peers
How does TMCI's PS Ratio compare to its peers?
|TMCI PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
FNA Paragon 28
BFLY Butterfly Network
LMAT LeMaitre Vascular
TMCI Treace Medical Concepts
Price-To-Sales vs Peers: TMCI is expensive based on its Price-To-Sales Ratio (11x) compared to the peer average (8.6x).
Price to Earnings Ratio vs Industry
How does TMCI's PE Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Sales vs Industry: TMCI is expensive based on its Price-To-Sales Ratio (11x) compared to the US Medical Equipment industry average (3.9x)
Price to Sales Ratio vs Fair Ratio
What is TMCI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||11x|
|Fair PS Ratio||9.7x|
Price-To-Sales vs Fair Ratio: TMCI is expensive based on its Price-To-Sales Ratio (11x) compared to the estimated Fair Price-To-Sales Ratio (9.7x).
Share Price vs Fair Value
What is the Fair Price of TMCI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate TMCI's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate TMCI's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Treace Medical Concepts forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TMCI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TMCI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TMCI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TMCI's revenue (21.7% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: TMCI's revenue (21.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TMCI is forecast to be unprofitable in 3 years.
Discover growth companies
How has Treace Medical Concepts performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: TMCI is currently unprofitable.
Growing Profit Margin: TMCI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if TMCI's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare TMCI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TMCI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (0.6%).
Return on Equity
High ROE: TMCI has a negative Return on Equity (-54.81%), as it is currently unprofitable.
Discover strong past performing companies
How is Treace Medical Concepts's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: TMCI's short term assets ($135.2M) exceed its short term liabilities ($16.6M).
Long Term Liabilities: TMCI's short term assets ($135.2M) exceed its long term liabilities ($70.4M).
Debt to Equity History and Analysis
Debt Level: TMCI has more cash than its total debt.
Reducing Debt: Insufficient data to determine if TMCI's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TMCI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: TMCI has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 74.9% each year.
Discover healthy companies
What is Treace Medical Concepts's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TMCI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TMCI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TMCI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TMCI's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as TMCI has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Treace (50 yo)
Mr. John T. Treace Founded Treace Medical Concepts, Inc. in 2014 and has been its Chief Executive Officer and Director since July 1, 2014. Before that, Mr. Treace served as Senior Vice President of U.S. Sa...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD688.15K) is below average for companies of similar size in the US market ($USD5.58M).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
Experienced Management: TMCI's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Experienced Board: TMCI's board of directors are considered experienced (7.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: TMCI insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|01 Sep 22||BuyUS$198,031||John Treace||Individual||10,000||US$19.80|
|26 Aug 22||BuyUS$450,342||John Treace||Individual||21,491||US$20.95|
|24 Aug 22||BuyUS$533,756||John Treace||Individual||28,509||US$18.92|
|18 May 22||BuyUS$97,960||Mark Hair||Individual||6,200||US$15.80|
|10 Mar 22||SellUS$38||J & A Group, LLC||Company||2||US$19.21|
|08 Mar 22||BuyUS$46,550||Terry Lubben||Individual||2,500||US$18.62|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Treace Medical Concepts, Inc.'s employee growth, exchange listings and data sources
- Name: Treace Medical Concepts, Inc.
- Ticker: TMCI
- Exchange: NasdaqGS
- Founded: 2014
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$1.255b
- Shares outstanding: 55.40m
- Website: https://www.treace.com
Number of Employees
- Treace Medical Concepts, Inc.
- 203 Fort Wade Road
- Suite 150
- Ponte Vedra
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|TMCI||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Apr 2021|
|7DW||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Apr 2021|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/23 00:00|
|End of Day Share Price||2022/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.